CytomX Therapeutics Company Profile (NASDAQ:CTMX)

About CytomX Therapeutics

CytomX Therapeutics logoCytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CTMX
  • CUSIP:
Key Metrics:
  • Previous Close: $11.66
  • 50 Day Moving Average: $11.54
  • 200 Day Moving Average: $12.25
  • 52-Week Range: $9.10 - $17.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.38
  • P/E Growth: -0.47
  • Market Cap: $420.44M
  • Outstanding Shares: 36,402,000
  • Beta: 1.1
Profitability:
  • Net Margins: -523.78%
  • Return on Equity: -52.50%
  • Return on Assets: -28.57%
Debt:
  • Current Ratio: 7.74%
  • Quick Ratio: 7.74%
Additional Links:
Companies Related to CytomX Therapeutics:

Analyst Ratings

Consensus Ratings for CytomX Therapeutics (NASDAQ:CTMX) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $20.50 (77.95% upside)

Analysts' Ratings History for CytomX Therapeutics (NASDAQ:CTMX)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017Cowen and CompanyReiterated RatingBuyView Rating Details
1/3/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform -> Market PerformView Rating Details
1/3/2017CannReiterated RatingHoldView Rating Details
3/16/2016Jefferies Group LLCReiterated RatingBuy$19.00View Rating Details
11/2/2015Bank of America CorpInitiated CoverageBuy$20.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2016        
5/6/2016($0.26)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytomX Therapeutics (NASDAQ:CTMX)
Current Year EPS Consensus Estimate: $-1.65 EPS
Next Year EPS Consensus Estimate: $-2.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.11)($0.25)
Q2 20162($0.44)($0.32)($0.38)
Q3 20162($0.42)($0.33)($0.38)
Q4 20162($0.49)($0.35)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CytomX Therapeutics (NASDAQ:CTMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CytomX Therapeutics (NASDAQ:CTMX)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 54.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.00View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CytomX Therapeutics (NASDAQ:CTMX)
DateHeadline
finance.yahoo.com logoCytomX Therapeutics to Present at Upcoming Investor Conferences (NASDAQ:CTMX)
finance.yahoo.com - February 21 at 5:19 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : February 14, 2017 (NASDAQ:CTMX)
www.capitalcube.com - February 14 at 3:45 PM
finance.yahoo.com logoCytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial (NASDAQ:CTMX)
finance.yahoo.com - February 2 at 4:59 PM
finance.yahoo.com logoCytomX to Present at Upcoming Investor Conferences (NASDAQ:CTMX)
finance.yahoo.com - February 2 at 4:59 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : January 31, 2017 (NASDAQ:CTMX)
www.capitalcube.com - January 31 at 5:05 PM
capitalcube.com logoETFs with exposure to CytomX Therapeutics, Inc. : January 17, 2017 (NASDAQ:CTMX)
www.capitalcube.com - January 17 at 5:25 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : January 13, 2017 (NASDAQ:CTMX)
www.capitalcube.com - January 13 at 5:19 PM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure (NASDAQ:CTMX)
biz.yahoo.com - January 10 at 5:28 PM
finance.yahoo.com logoUPDATE: CytomX Announces Time Change for its Presentation at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:CTMX)
finance.yahoo.com - January 9 at 9:12 PM
finance.yahoo.com logoCytomX to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:CTMX)
finance.yahoo.com - January 9 at 4:11 PM
marketexclusive.com logoAnalyst Activity – Oppenheimer Holdings, Inc. Reiterates Outperform on CytomX Therapeutics (NASDAQ:CTMX) (NASDAQ:CTMX)
marketexclusive.com - January 3 at 6:12 PM
us.rd.yahoo.com logoCytomX Therapeutics downgraded by Oppenheimer (NASDAQ:CTMX)
us.rd.yahoo.com - January 3 at 12:41 PM
capitalcube.com logoCytomX Therapeutics, Inc. – Value Analysis (NASDAQ:CTMX) : December 27, 2016 (NASDAQ:CTMX)
www.capitalcube.com - December 27 at 12:06 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : December 26, 2016 (NASDAQ:CTMX)
www.capitalcube.com - December 26 at 11:39 AM
us.rd.yahoo.com logoCytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072 (NASDAQ:CTMX)
us.rd.yahoo.com - December 14 at 5:35 PM
us.rd.yahoo.com logo8:08 am CytomX Therapeutics announces that Bristol-Myers Squibb (BMY (NASDAQ:CTMX)
us.rd.yahoo.com - December 13 at 5:14 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : December 13, 2016 (NASDAQ:CTMX)
us.rd.yahoo.com - December 13 at 8:40 AM
us.rd.yahoo.com logoCytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration (NASDAQ:CTMX)
us.rd.yahoo.com - December 13 at 8:40 AM
capitalcube.com logoETFs with exposure to CytomX Therapeutics, Inc. : December 9, 2016 (NASDAQ:CTMX)
www.capitalcube.com - December 9 at 4:51 PM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CTMX)
us.rd.yahoo.com - December 6 at 4:48 PM
finance.yahoo.com logo8:09 am CytomX Therapeutics announces the selection of the fourth target by Bristol-Myers Squibb (BMY (NASDAQ:CTMX)
finance.yahoo.com - December 5 at 12:11 PM
capitalcube.com logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 (NASDAQ:CTMX)
www.capitalcube.com - November 22 at 4:03 PM
finance.yahoo.com logoCytomX to Present at the Jefferies 2016 London Healthcare Conference (NASDAQ:CTMX)
finance.yahoo.com - November 9 at 9:07 PM
einnews.com logoCytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update (NASDAQ:CTMX)
brazilbusiness.einnews.com - November 3 at 10:01 PM
sg.finance.yahoo.com logoCytomX Therapeutics reports 3Q loss (NASDAQ:CTMX)
sg.finance.yahoo.com - November 3 at 10:01 PM
biz.yahoo.com logoQ3 2016 CytomX Therapeutics Inc Earnings Release - After Market Close (NASDAQ:CTMX)
biz.yahoo.com - November 3 at 8:35 AM
publicnow.com logoCytomX Therapeutics to Announce Third Quarter 2016 Financial Results (NASDAQ:CTMX)
www.publicnow.com - October 27 at 9:02 AM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : October 21, 2016 (NASDAQ:CTMX)
www.capitalcube.com - October 21 at 4:32 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : October 13, 2016 (NASDAQ:CTMX)
www.capitalcube.com - October 13 at 4:25 PM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : September 23, 2016 (NASDAQ:CTMX)
www.capitalcube.com - September 23 at 4:15 PM
News IconCanaan Partners Adds Joydeep Bhattacharyya and Rich Boyle As Partners (NASDAQ:CTMX)
www.finsmes.com - September 21 at 5:01 PM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : September 12, 2016 (NASDAQ:CTMX)
www.capitalcube.com - September 12 at 4:17 PM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : August 23, 2016 (NASDAQ:CTMX)
www.capitalcube.com - August 23 at 4:36 PM
capitalcube.com logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:CTMX)
www.capitalcube.com - August 10 at 4:36 PM
sg.finance.yahoo.com logoCytomX Therapeutics reports 2Q loss (NASDAQ:CTMX)
sg.finance.yahoo.com - August 3 at 10:07 PM
publicnow.com logoCytomX Announces Second Quarter 2016 Financial Results (NASDAQ:CTMX)
www.publicnow.com - August 3 at 4:35 PM
biz.yahoo.com logoQ2 2016 CytomX Therapeutics Inc Earnings Release - After Market Close (NASDAQ:CTMX)
biz.yahoo.com - August 3 at 9:57 AM
finance.yahoo.com logoCytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update (NASDAQ:CTMX)
finance.yahoo.com - July 27 at 4:30 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : July 27, 2016 (NASDAQ:CTMX)
www.capitalcube.com - July 27 at 8:15 AM
capitalcube.com logoCytomX Therapeutics, Inc. – Value Analysis (NASDAQ:CTMX) : July 18, 2016 (NASDAQ:CTMX)
www.capitalcube.com - July 18 at 3:38 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : July 11, 2016 (NASDAQ:CTMX)
www.capitalcube.com - July 11 at 8:04 AM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V (NASDAQ:CTMX)
biz.yahoo.com - June 13 at 4:06 PM
publicnow.com logoCytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors (NASDAQ:CTMX)
www.publicnow.com - June 13 at 8:19 AM
capitalcube.com logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 (NASDAQ:CTMX)
www.capitalcube.com - June 1 at 12:30 PM
4-traders.com logoCytomX Therapeutics : to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:CTMX)
www.4-traders.com - May 26 at 1:43 PM
publicnow.com logoCytomX to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:CTMX)
www.publicnow.com - May 24 at 8:16 AM
fidaily.com logoCytomX Therapeutics, Inc. (CTMX) Investment Down in Latest Report from Deerfield Management Co - Finance Daily (NASDAQ:CTMX)
www.fidaily.com - May 18 at 11:56 AM
finance.yahoo.com logoCYTOMX THERAPEUTICS, INC. Financials (NASDAQ:CTMX)
finance.yahoo.com - May 13 at 1:04 PM
thestreet.com logoCytomX Therapeutics is Now Oversold (CTMX) (NASDAQ:CTMX)
www.thestreet.com - May 13 at 11:35 AM
News IconConsensus Rating Review for CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential (NASDAQ:CTMX)
www.bodyconfidential.com - May 11 at 11:41 AM

Social

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Where is CytomX Therapeutics' stock going? Where will CytomX Therapeutics' stock price be in 2017?

4 equities research analysts have issued twelve-month target prices for CytomX Therapeutics' stock. Their forecasts range from $19.00 to $22.00. On average, they anticipate CytomX Therapeutics' share price to reach $20.50 in the next year.

When will CytomX Therapeutics announce their earnings?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 21st 2016.

What are analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:

  • According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (2/14/2017)

  • Cowen and Company analysts commented, "CTMX announced this morning that the first patient has been dosed in CX-072’s." (2/2/2017)

  • Cann analysts commented, "We are changing our rating for CytomX, a high-quality development-stage, platform technology company with a strong management team and novel science, from Outperform to Perform, and removing our $22 price target. We anticipate CytomX will launch its first drug, CX-072, in 2023." (1/3/2017)

Who owns CytomX Therapeutics stock?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Putnam Investments LLC (3.75%), Deerfield Management Co. (2.59%), Perceptive Advisors LLC (2.54%), Franklin Resources Inc. (0.92%) and State Street Corp (0.76%). Company insiders that own CytomX Therapeutics stock include Cynthia J Ladd, Frederick W Gluck, Ix LP Canaan, James E Flynn and Timothy M Shannon.

Who sold CytomX Therapeutics stock? Who is selling CytomX Therapeutics stock?

CytomX Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC. Company insiders that have sold CytomX Therapeutics stock in the last year include Ix LP Canaan and Timothy M Shannon.

Who bought CytomX Therapeutics stock? Who is buying CytomX Therapeutics stock?

CytomX Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Renaissance Technologies LLC, Oxford Asset Management, Russell Investments Group Ltd., FMR LLC, Trexquant Investment LP, Harbourvest Partners LLC and Opaleye Management Inc.. Company insiders that have bought CytomX Therapeutics stock in the last two years include Cynthia J Ladd, Frederick W Gluck and James E Flynn.

How do I buy CytomX Therapeutics stock?

Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CytomX Therapeutics stock cost?

One share of CytomX Therapeutics stock can currently be purchased for approximately $11.52.

CytomX Therapeutics (NASDAQ:CTMX) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Earnings History Chart

Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Dividend History Chart

Dividend Payments by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Last Updated on 2/24/2017 by MarketBeat.com Staff